Last reviewed 2026-04-19 · How we verify

MK0518

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Insomnia
• Fatigue
• Nausea
• Asthenia
• Headache
• Myopathy
• Rhabdomyolysis
• Abnormal dreams
• Creatine kinase elevations
• Discontinuation of therapy due to adverse reactions
• Absolute neutrophil count decrease
• Hemoglobin decrease

Key clinical trials

• A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (PHASE4)
• Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
• A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
• Pregnancy, Anti-integrase and Lymphocyte Repertoire of the Newborn
• Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
• Therapeutic Drug Monitoring to oPtimize ANtiretroviral regimeNs in HIV-infected Women Who wAnt to Breastfeed
• Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• MK0518 CI brief — competitive landscape report
• MK0518 updates RSS · CI watch RSS
• Merck Sharp & Dohme LLC portfolio CI